Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B

Affiliations

¹ Vestfold Hospital Trust, Department of Infectious Diseases, 3103 Tønsberg, Norway; University of Oslo, Sustainable Health Unit (SUSTAINIT), Oslo, Norway. Electronic address: uxasoh@siv.no.

Comment

Asgeir Johannessen. Lancet Gastroenterol Hepatol. 2025 Apr.

. 2025 Apr;10(4):276-277.

doi: 10.1016/S2468-1253(25)00008-1. Epub 2025 Feb 3.

¹ Vestfold Hospital Trust, Department of Infectious Diseases, 3103 Tønsberg, Norway; University of Oslo, Sustainable Health Unit (SUSTAINIT), Oslo, Norway. Electronic address: uxasoh@siv.no.

No abstract available

Conflict of interest statement

I declare no competing interests.

Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial.
Lim YS, Yu ML, Choi J, Chen CY, Choi WM, Kang W, Kim GA, Kim HJ, Lee YB, Lee JH, Park NH, Kwon SY, Park SY, Kim JH, Choi GH, Jang ES, Chen CH, Hsu YC, Bair MJ, Cheng PN, Tung HD, Chang TS, Lo CC, Tseng KC, Yang SS, Peng CY, Han S. Lim YS, et al. Lancet Gastroenterol Hepatol. 2025 Apr;10(4):295-305. doi: 10.1016/S2468-1253(24)00431-X. Epub 2025 Feb 3. Lancet Gastroenterol Hepatol. 2025. PMID: 39914435 Clinical Trial.